Advertisement
Screener

AGENUS INC (AGEN) Overview

AGENUS INC (AGEN) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.01; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 1.02; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 1.94; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -1.00; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$2.63$3.46$4.56$6.00$7.89$10.382025-11-062026-11-06$1.43$3.29$7.57$17.38$39.93$91.712021-11-082026-11-06$1.43$3.57$8.88$22.08$54.93$136.642016-11-072026-11-06$1.43$4.71$15.47$50.80$166.81$547.772006-11-062026-11-06$1.43$7.73$41.63$224.24$1,207.96$6,507.112000-02-082026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$7.14
Previous close
$9.89
Change
-$2.75
Change (%)
-27.81%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

AGEN
+214.97%
S&P 500
(m)

1 year

AGEN
+148.49%
S&P 500
(m)

3 years

AGEN
-56.24%
S&P 500
(m)

5 years

AGEN
-90.38%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.01

-1.11-0.300.511.312.1231 Mar 2025: estimate (m); actual -1.0331 Mar 2025(m)30 Jun 2025: estimate (m); actual -1.0030 Jun 2025(m)30 Sept 2025: estimate (m); actual 1.9430 Sept 2025(m)31 Mar 2026: estimate (m); actual 1.0231 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.0130 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.01(m)(m)
1 Jan 202631 Mar 2026(m)1.02(m)(m)
1 Jul 202530 Sept 2025(m)1.94(m)(m)
1 Apr 202530 Jun 2025(m)-1.00(m)(m)
1 Jan 202531 Mar 2025(m)-1.03(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 0.00

-15.72-11.75-7.77-3.790.1831 Dec 2021: estimate (m); actual -0.1131 Dec 2021(m)31 Dec 2022: estimate (m); actual -15.6431 Dec 2022(m)31 Dec 2023: estimate (m); actual -13.7531 Dec 2023(m)31 Dec 2024: estimate (m); actual -10.5931 Dec 2024(m)31 Dec 2025: estimate (m); actual 0.0031 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)0.00(m)(m)
1 Jan 202431 Dec 2024(m)-10.59(m)(m)
1 Jan 202331 Dec 2023(m)-13.75(m)(m)
1 Jan 202231 Dec 2022(m)-15.64(m)(m)
1 Jan 202131 Dec 2021(m)-0.11(m)(m)

Revenue vs. Earnings

USD

31 Dec 2020 ■ Revenue 31.27M ■ Earnings -37.73M — Profit margin -120.68%

-61.60M-349.2%-27.33M-272.7%6.94M-196.2%41.21M-119.7%31 Mar 2020: revenue 15.13M; earnings -45.27M; profit margin -299.25%31 Mar 202030 Jun 2020: revenue 26.95M; earnings -48.24M; profit margin -179.05%30 Jun 202030 Sept 2020: revenue 14.83M; earnings -51.65M; profit margin -348.21%30 Sept 202031 Dec 2020: revenue 31.27M; earnings -37.73M; profit margin -120.68%31 Dec 2020

31 Dec 2025 ■ Revenue 114.20M ■ Earnings -3.08M — Profit margin -2.70%

-307.09M-282.5%-136.07M-188.9%34.95M-95.3%205.96M-1.7%31 Dec 2017: revenue 42.88M; earnings -120.69M; profit margin -281.49%31 Dec 201731 Dec 2023: revenue 156.31M; earnings -257.44M; profit margin -164.69%31 Dec 202331 Dec 2024: revenue 103.46M; earnings -232.27M; profit margin -224.50%31 Dec 202431 Dec 2025: revenue 114.20M; earnings -3.08M; profit margin -2.70%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$7.14(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$7.14High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning AGEN

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
316.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.05M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
13.68%*
Total return · month
29.11%*
Total return · quarter
213.97%*
Total return · half year
191.74%*
Total return · year to date
214.97%*
Total return · 1 year
148.49%*
Total return · 3 years
-56.24%*
Total return · 5 years
-90.38%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$132.69M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

AGENUS INC Overview

View more →

(m)

(m)

SEC CIK
1098972
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Country of operation
United States
Business address
3 FORBES ROAD, LEXINGTON, Massachusetts, 02421, United States
Fiscal year end
1231
Phone
781-674-4410

Similar stocks

Stock NameCountryMarket CapPE Ratio
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
Surrozen, Inc./DE (SRZN)United States$0.395B
Zura Bio Ltd (ZURA)$0.398B-6.56
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Ocugen, Inc. (OCGN)United States$0.343B-6.34
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60